MedTrace Logo

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

NCT05332925 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-02-23

No results posted yet for this study

Summary

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.

Conditions

Interventions

DRUG

Standard of care immune checkpoint inhbitors

This is NOT an interventional study.

Sponsors & Collaborators

  • Nilogen Oncosystems

    collaborator INDUSTRY

  • Jun Zhang, MD, PhD

    lead OTHER

Principal Investigators

  • Jun Zhang, MD, PhD · University of Kansas Medical Center

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2026-01-31
Completion
2027-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05332925 on ClinicalTrials.gov